1. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion;Bandello;European Journal of Ophthalmology,2018
2. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results
3. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion clinicaltrials.gov/ct2/show/NCT01427751
4. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom) ClinicalTrials.gov/show/NCT01976338
5. Wei W To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Annual Meeting of the Association for Research in Vision and Ophthalmology 2017